Gastroesophageal Reflux Clinical Trial
Official title:
A Prospective Assessment of pH Testing Methods in Alberta
Gastroesophageal reflux disease (GERD) is a common and potentially debilitating disorder.
Typical symptoms include heartburn and regurgitation of acid tasting substances. GERD is a
chronic disease and in some cases, more alarming symptoms including food sticking in the
esophagus, pain with swallowing, bleeding, anemia and weight loss develop.
In Alberta, upper endoscopy is the first line of investigation accompanied by an ambulatory
24-hour esophageal pH monitoring for patients with symptoms that are unresponsive to
acid-suppressing therapy or who exhibit alarm symptoms.
Current standard of care in Alberta for esophageal pH monitoring first requires an
esophageal manometry test to identify the location of the lower esophageal sphincter
followed by the placement of a thin catheter with one or more pH probes inserted through the
nose and taped in place to the face for 20 -24 hours. The patient wears a small battery
powered data logger and maintains a diary of GERD symptoms and activity. This system enables
the recording and correlation of specific symptoms with reflux episodes over extended
periods and provides direct evidence of GERD. The nasally passed pH catheter is
uncomfortable and restrictive for some patients often resulting in abnormal eating,
drinking, activity and sleeping patterns. The data collected may not be representative of
the patient's typical experience and may not reflect the true severity of the disease.
A wireless diagnostic pH monitoring system called Bravo pH Monitoring System developed by
Medtronic is approved for use in Canada and is commercially available. This system
eliminates the need for a catheter by utilizing a capsule the size of a gel-cap and radio
frequency technology to monitor esophageal pH. It has been shown to be safe and as sensitive
as conventional catheter-based pH probe monitoring. The Bravo system can be sited either
endoscopically or manometrically.
The goal of this study is to test the Bravo Wireless pH system in Alberta using manometric
siting to assess feasibility, patient outcomes and tolerance.
Hypotheses:
1. Patient tolerance of the Bravo system is superior to standard pH-metry.
2. Manometric placement of Bravo is as successful as standard pH-metry.
Our aims:
1. To assess patient tolerance of Bravo versus standard pH-metry.
2. To compare the success rate of manometric peroral placement of Bravo pH probe versus
standard pH-metry.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |